Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29966680 | 1.00 | RIPK1 (0.39) | RIPK1PIK3R1PIK3CADPP4GPR119 | |
| SCHEMBL28873169 | 1.00 | RIPK1 (0.39) | RIPK1PIK3R1PIK3CADPP4GPR119 | |
| SCHEMBL30339166 | 0.91 | RIPK1 (0.34) | RIPK1PIK3R1PIK3CADPP4GPR119 | |
| SCHEMBL18921502 | 0.85 | RIPK1 (0.39) | RIPK1ALDH1A1ABL1 | |
| SCHEMBL30338931 | 0.84 | RIPK1 (0.42) | RIPK1PIK3R1PIK3CAGPR119 | |
| SCHEMBL29048238 | 0.84 | RIPK1 (0.42) | RIPK1PIK3R1PIK3CAGPR119 | |
| SCHEMBL30338821 | 0.84 | RIPK1 (0.42) | RIPK1PIK3R1PIK3CAGPR119 | |
| SCHEMBL29048328 | 0.84 | RIPK1 (0.42) | RIPK1PIK3R1PIK3CAGPR119 | |
| SCHEMBL18921383 | 0.83 | RIPK1 (0.41) | RIPK1ABL1 | |
| SCHEMBL22608904 | 0.82 | NTRK1 (0.42) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116547281-A | Isoxazolidines as RIPK1 inhibitors and uses thereof | 赛诺菲 | 2023-08-04 | — | — | CN | disclosed |
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | DENALI THERAPEUTICS INC. (US) | 2020-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10709692-B2 | Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1) | RIPK1, RIPK2, RIPK3 | RIPK1 1/4885PIK3R1 293/4885PIK3CA 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.